logo-loader
viewAthersys

Athersys CEO highlights progress of lead therapy MultiStem to help stroke patients

Athersys Inc (NASDAQ: ATHX) CEO Dr. Gil Van Bokkelen together with patient and stroke victim Sharon Thomas joined Proactive Investors in New York to discuss how MultiStem, Athersys' lead therapy, is progressing through the drug-development cycle.

Thomas was treated with MultiStem when the drug was in Phase 2. It has since progressed to Phase 3 with FDA Fast Track designation. What's more, a separate clinical program evaluating MultiStem cell therapy for the treatment of Acute Respiratory Distress Syndrome has received Fast Track designation.

Quick facts: Athersys

Price: 2.97 USD

NASDAQ:ATHX
Market: NASDAQ
Market Cap: $584.45 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen CEO details expansion of key coronavirus trial to patients in home

Synairgen PLC's (LON:SNG) CEO Richard Marsden caught up with Proactive London's Andrew Scott after announcing that the trial of its SNG001 interferon-beta treatment will be extended to coronavirus patients in the home environment. He says the idea behind the move is to dose patients with the...

11 hours, 3 minutes ago

2 min read